Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.
Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.
复制标题
DOI:
10.1158/1078-0432.ccr-08-0738
复制
发表时间:
2008-07-01
期刊:
影响因子:
--
通讯作者:
Lokeshwar BL
中科院分区:
文献类型:
--
作者:
Caruso DJ;Carmack AJ;Lokeshwar VB;Duncan RC;Soloway MS;Lokeshwar BL
Lack of reliable biomarkers limits accurate prediction of PSA biochemical recurrence (disease progression) in prostate cancer (CaP). The two inflammatory chemokines, Osteopontin (OPN) and interleukin-8 (IL-8) are associated with tumor angiogenesis and metastasis. We investigated whether OPN and IL-8 expression in CaP correlates with disease progression. Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72 month follow-up. OPN and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of OPN and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models. In tumor cells, OPN and IL-8 staining was higher in the recurred group (203.2 ± 78.4; 181.1 ± 89.3) than in the non-recurred group (122.7 ± 76.6; 96.4 ± 85.6; p < 0.001). Higher OPN and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in non-recurred group. In univariate analysis, except age, all pre- and post-operative parameters and OPN and IL-8 staining scores significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and OPN staining independently associated with biochemical recurrence within 72 months. OPN, either alone or with IL-8 and seminal vesicle invasion was a significant parameter in predicting biochemical recurrence within 24 months. OPN and IL-8 staining predicted recurrence with high sensitivity (75.5% 73.6%) and specificity (76%, 70.6%). In prostatectomy specimens, OPN expression is independently associated with biochemical recurrence. Both OPN and IL-8 may be predictors of early disease progression.